JUBLPHARMA1,026.00

Jubilant Pharmova Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersGLANDPPLPHARMAKIMSINDGNONESOURCEGRANULESPFIZERPOLYMEDMcap ₹16,211 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue from Operations6,702.97,234.58,279.68,608.3
Other Income68.756.866.073.9
Total Income6,771.67,291.38,345.68,682.2
Expenses
+ Cost of Materials Consumed1,821.31,985.32,320.32,438.1
+ Purchases of Stock-in-Trade241.2297.1313.1327.0
+ Changes in Inventories78.234.610.99.7
+ Employee Benefit Expense2,216.02,267.92,700.62,863.0
+ Finance Costs272.3240.3211.8217.0
+ Depreciation & Amortisation381.9368.6440.4469.6
+ Other Expenses1,445.41,475.91,674.91,752.3
Total Expenses6,456.36,669.77,672.08,076.7
EBITDA900.81,173.71,259.81,218.2
EBIT518.9805.1819.4748.6
Profit
PBT before Exceptional Items315.3621.6673.6605.5
+ Exceptional Items-168.9359.5-59.2-59.2
Pretax Income146.4981.1614.4546.3
+ Current Tax202.6213.2160.7152.8
+ Deferred Tax-104.8-68.955.941.9
Tax Expense97.8144.3216.6194.7
+ Share of Associates & JVs24.1-0.5-0.3-0.2
Net Income72.7836.3397.5351.4
+ Net Income — Continuing Ops48.6836.8397.8351.6
+ Other Comprehensive Income54.485.0545.8485.6
Total Comprehensive Income127.1921.3943.3837.0
Net Income to Common77.1839.4398.5352.1
Minority Interest-4.4-3.1-1.0-0.7
Per Share
Basic EPS4.8752.9925.1522.23
Diluted EPS4.8652.8525.0822.17
Other Comprehensive Income — detail
+ Other Comprehensive Income85.0545.8485.6
+ Items NOT to be Reclassified to P&L5.8-0.36.46.9
+ Tax on Items NOT to be Reclassified1.1-0.8-0.10.0
+ Tax on Items NOT to be Reclassified — alt tag1.1
+ Items to be Reclassified to P&L49.784.5
+ Tax on Items to be Reclassified0.0-539.3-274.6
Comprehensive Income — Owners of Parent131.7924.7944.9838.2
Comprehensive Income — Non-controlling Interests-4.6-3.4-1.6-1.2
Per Share — as-filed variants
Basic EPS — Continuing Operations4.8752.9925.1522.23
Diluted EPS — Continuing Operations4.8652.8525.0822.17
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit4,562.24,917.55,635.35,833.5
Gross Margin %68.0667.9768.0667.77
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)315.3621.6673.6605.5
− Exceptional Items (reconciliation)-168.9359.5-59.2-59.2
Net Income Adj (tax-effected)140.3529.7435.8389.5
EPS Adj9.4033.5627.5824.64
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value1.001.001.001.00
Paid Up Equity Capital15.815.815.815.8
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.